News

  • Meeting of consortium members to discuss project advances and plans.

    September 29 2025

    Members Left to Right: Dr Grant McNaughton-Smith (FICIC) Dr Javier Martinez-Useros(FJD-IIS), Dra Judith Hernández Garces (CEAMED SA) and Sara Thovar Iceta (IPNA-CSIC).

  • Dr Grant McNaughton-Smith was invited to speak at the Advances in Biomedical REsearch symposium (ABRE2025)

    TENERIFE, SPAIN, JULY 21-23, 2025

    Title of presentation: Agonists of Caseinolytic Protease P (ClpP) as potential anticancer and antibacterial drugs. The highs and lows of drug discovery.

    The presentation covered the history behind the discovery of HsClpP agonists as new potential anticancer agents, and how the CLIP-CAN project will seek to develop new and improved HsClpP agonists, to treat various resistant cancers.

    The full video can be watched upon request.

  • First, in-person, meeting of the CLIP-CAN consortium

    March 28th 2025, Torre Profesor Agustín, San Cristobal de La Laguna (Sede de CEAMED SA)

    Members from CEAMED SA (Dra Sara Marrerro Hernández and Dra Judith Hernández Garces), IPNA-CSIC (Dr Antonio Hernandez Daranas and Sara Thovar Iceta), FIIS-FJD (Dr Javier Martinez-Useros) and FICIC (Dr Grant McNaughton-Smith) discussing plans and objectives.

  • Incorporation of Dr Sara Marrero Hernández and Dr Judith Hernández Garcés into CEAMED SA as part of the CLIP-CAN project

    January 8th 2025

    CEAMED is please to annouce the incorporation of Dr Sara Marrero Hernández and Dr Judith Hernández Garces into the CEAMED family.

    Dr Sara Marrero Hernández is a biologist with over 10 years of experience in applied research, specializing in microbiology, cellular biology, and molecular biology. Sara has participated in international projects in Italy, Spain and Australia. Sara will oversee the biological requirements of the project and will coordinate with our members in FICIC, FIIS-FJD and IPNA-CSIC.

    Dr Judith Hernández Garces has a degree in pharmacy and a PhD in Chemistry and Chemical Engineering. During her thesis Judith designed and synthesized new compounds inspired by privileged structures found in natural products and assessed their activities in cancer cells. Judith will be our lead chemist on this project.

    The incorporation of both Sara and Judith has been facilitated by the funding provided by the Ministry of Science, Innovation and Universities (see funding page).

    Dr Sara Marrero Hernández Dr Judith Hernández Garces

  • Publication of European patent application describing new HsClpP agonists by CEAMED SA (EP 4488279)

    January 2025

  • Publication of PCT patent application describing new HsClpP agonists by CEAMED SA (WO 2025/008381)

    Compounds within the patent application are agonists of HsClpP that possess interesting in vitro activities against a variety of human derived cancer cell lines.